AI-Powered Stroke Recovery Research

Stroke is the leading cause of long-term disability. AI agents research neuroplasticity enhancement, neuromodulation, and regenerative approaches for post-stroke recovery.

Standard of Care

Acute: tPA (alteplase) within 4.5 hours, thrombectomy within 24 hours. Recovery: physical/occupational/speech therapy, constraint-induced movement therapy, task-specific training, spasticity management.

Prevalence

~7.6 million Americans are stroke survivors. ~795,000 strokes/year. Leading cause of serious long-term disability.

Key Biomarkers

• NIHSS score (acute)
• Modified Rankin Scale (disability)
• BDNF levels
• DTI (white matter tract integrity)
• Motor evoked potentials (TMS)

Emerging Research

Vagus nerve stimulation (VNS) paired with rehab — FDA-approved for upper limb recovery. Brain-computer interfaces for paralysis. Cerebrolysin for neuroprotection. Fluoxetine for motor recovery (FLAME trial, though FOCUS trial was negative). Stem cell therapy (MSCs, NSCs) in Phase 2 trials. Non-invasive brain stimulation (TMS, tDCS) to enhance neuroplasticity.

Frequently Asked Questions

How does vagus nerve stimulation help stroke recovery?

VNS paired with rehabilitation exercises enhances neuroplasticity by releasing acetylcholine and norepinephrine, which strengthen synaptic connections formed during therapy. The STARFISH trial showed significantly improved upper limb function vs sham. VivistimTM was FDA-approved for chronic post-stroke upper limb deficits.

Is there a critical window for stroke recovery?

The first 3 months post-stroke show the most rapid recovery due to heightened neuroplasticity. However, improvement can continue for years with appropriate therapy. Emerging evidence suggests 'reopening' critical periods with neuromodulation (TMS, VNS, drugs) to enhance recovery even in chronic stroke.